MBJ is engaged in fermentation-based research, development and manufacturing of pharmaceuticals, specialty chemicals and CDMO services. The Japanese company has capabilities across oncology APIs, plasmid DNA manufacturing, ADC conjugation and biologics.

MBJ reported estimated revenue of JPY 9.5 billion, or around Rs 570 crore, for FY26. Around 40% of its revenue comes from overseas markets outside Japan.

Gujarat Themis said the acquisition marks a strategic step in its transition from a fermentation-led intermediates business to a technology-driven Contract Development and Manufacturing Organisation (CDMO) platform focused on precision fermentation and next-generation drug manufacturing.

The company added that the deal will provide access to MBJ’s proprietary technologies, global customer relationships and regulated manufacturing infrastructure. Two of MBJ’s three manufacturing facilities in Japan have undergone audits by the US FDA and Japan’s PMDA.

The acquisition is proposed to be funded through a mix of debt and equity and is expected to be earnings accretive.

Gujarat Themis Biosyn is a pharmaceutical company engaged in the development, manufacturing and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company specializes in fermentation-based product development and continues to expand its presence across the Indian and global markets with a focus on building an integrated and scalable pharmaceutical platform.

On a standalone basis, Gujarat Themis Biosyn's net profit declined 3.93% to Rs 12.46 crore while net sales rose 9.74% to Rs 43.37 crore in Q3 December 2025 over Q3 December 2024.